Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C

Hepatology

Volumn 60, Issue 3, 2014, Pages 832-843

  Tsochatzis, Emmanuel A ^a   Crossan, Catriona ^b   Longworth, Louise ^b   Gurusamy, Kurinchi ^c   Rodriguez Peralvarez, Manolo ^a   Mantzoukis, Konstantinos ^a   O'Brien, Julia ^a   Thalassinos, Evangelos ^a   Papastergiou, Vassilios ^a   Noel Storr, Anna ^d   Davidson, Brian ^c   Burroughs, Andrew K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b BRUNEL UNIVERSITY   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ELASTOGRAPHY; EMBASE; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; META ANALYSIS; NONINVASIVE TEST; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DECISION MAKING; ELASTICITY IMAGING TECHNIQUES; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; PREDICTIVE VALUE OF TESTS;

EID: 84906793894     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27296     Document Type: Article

References (31)

1. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-264.
3. Afdhal NH, Lok AS, Di Bisceglie AM. Clinical decisions. Management of incidental hepatitis C virus infection. N Engl J Med 2009;360:1902-1906.
4. Martinez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011;53:325-335.
5. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-536.
6. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982-990.
7. Takwoingi Y, Deeks JJ. MetaDAS: a SAS macro for meta-analysis of diagnostic accuracy studies. USER Guide Version 1.3. Available from: http://srdtacochraneorg/sites/srdtacochraneorg/files/uploads/MetaDAS Readmev13May 2012 pdf. Accessed October 25, 2012.
8. Liu S, Schwarzinger M, Carrat F, Goldhaber-Fiebert JD. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. PLoS ONE 2011;6:e26783.
9. Wright M, Grieve R, Roberts J, Main J, Thomas HC, Alexander G, et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomized controlled trial and economic evaluation. Health Technol Assess 2006;10:iii-93.
10. van der Meer AJ, Hansen BE, Fattovich G, Feld JJ, Wedemeyer H, Dufour JF, et al. Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. Gut 2014 May 9. doi: 10.1136/gutjnl-2013-305357. [Epub ahead of print].
11. National Institute for Health and Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal. London: NICE; 2013.
12. National Institute for Health and Clinical Excellence (NICE). Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. In: NICE Technology Appraisal Guidance 106. London: NICE; 2007.
13. National Institute for Health and Clinical Excellence (NICE). Boceprevir for the treatment of genotype 1 chronic hepatitis C. In: Technology Appraisal Guidance 253. London: NICE; 2012.
14. National Institute for Health and Clinical Excellence (NICE). Telaprevir for the treatment of genotype 1 chronic hepatitis C. In: NICE Technology Appraisal Guidance 252: NICE; 2012.
15. National Institute for Health and Clinical Excellence (NICE). Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. In: Part Review of NICE Technology Appraisal Guidance 75 and 106. London: NICE; 2010.
16. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72.
17. Longworth L, Young T, Buxton MJ, Ratcliffe J, Neuberger J, Burroughs A, Bryan S. Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups. Liver Transpl 2003;9:1295-1307.
18. Drummond M, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford, UK: Oxford University Press, 1997.
19. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-787.
20. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon α-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess 2004;8:iii-iv, 1-125.
21. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.
22. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013;158:807-820.
23. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011;54:650-659.
24. Deuffic-Burban S, Schwarzinger M, Mallet V, Pol S, Pageaux GP, Canva-Delcambre V, et al. Immediate or delayed treatment initiation with "Previr" containing regimens in HCV-infected naive genotype 1 (G1) patients without severe fibrosis? A cost effectiveness analysis (ANRS No 12188). J Hepatol 2013;58(Suppl. 1):S331.
25. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 2012;157:817-822.
26. van der Meer AJ, Wedemeyer H, Feld JJ, Hansen BE, Manns MP, Zeuzem S, Janssen HL. Is there sufficient evidence to recommend antiviral therapy in hepatitis C? J Hepatol 2014;60:191-196.
27. Wright M, Grieve R, Roberts J, Main J, Thomas HC. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006;10:1-113, iii.
28. Fried MW, Shiffman ML, Rajender Reddy K, Smith C, Marinos G, Gonçales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
29. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006;55:1350-1359.
30. Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, et al. Peginterferon α-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005;54:858-866.
31. Grishchenko M, Grieve RD, Sweeting MJ, De Angelis D, Thomson BJ, Ryder SD, Irving WL. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care 2009;25:171-180.